Proprietary technology developed through $15M of New Zealand Government R&D investment, validated by world-leading microbiology expertise.

The Science of Resistance

Antimicrobial resistance is the result of evolutionary pressure. Bacteria exposed to antibiotics develop and share mechanisms, such as enzymatic degradation, efflux pumps, target modification, and biofilm formation, that allow them to survive treatment. Once these mechanisms spread, the antibiotic stops working.

The traditional response has been to develop new antibiotics. But the pipeline is thin, the development costs are high, and resistance often emerges before a new drug is widely deployed.

Viropin takes a different approach. Rather than chase new molecules, we disrupt the resistance mechanisms themselves; restoring the activity of antibiotics that are already trusted, manufactured at scale, and familiar to clinicians.

Our Platform

Viropin's technology is the product of years of laboratory development supported by $15M in New Zealand Government R&D funding. It is protected by multiple internationally granted patents and proprietary formulations.

The platform supports two distinct product lines, infection-control products and antibiotic restoration therapies, from a shared scientific foundation. This is what makes Viropin capital-efficient: one platform, multiple revenue pathways, parallel development timelines.

Data Available Under NDA

For qualified investors, partners, and collaborators, Viropin can provide:

• Minimum Inhibitory Concentration (MIC) data

• Pathogen panel results

• Resistance mechanism characterisation

• Toxicity profiles

• Ames test data

Scientific Leadership

Viropin's scientific programme is led by Dr Paul Spence (DPhil Molecular Virology, Oxford), one of the original inventors of NAMZARIC®, the combination Alzheimer's therapy.

Our lead microbiologist is Professor Greg Cook, Deputy Vice-Chancellor (Research & Innovation) at the University of Otago and a globally recognised expert in bacterial physiology and antimicrobial resistance.

Together with Chief Innovation Officer Dr Anna Campbell and a cross-disciplinary team across New Zealand, Australia, the United Kingdom, the Middle East, and China, Viropin combines world-class science with the commercial experience needed to bring products to market.